

THE UNIVERSITY OF MICHIGAN

REGENTS COMMUNICATION

ACTION REQUEST

Subject: Research Agreement between the University of Michigan and Ascentage Pharma Group Corporation, Ltd.

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Division of Research Development and Administration while reviewing the proposed Agreement. This triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflicts of interest was then developed by the Board and agreed to by the parties involved.

The proposed Agreement ("Agreement") falls under the State of Michigan Conflict of Interest Statute because Dr. Shaomeng Wang is both an employee of the University of Michigan ("University") and co-founder, stockholder with a significant financial interest, Director, and Consultant to Ascentage Pharma Group Corporation, Ltd. ("Company"). The law permits such an Agreement provided it is disclosed to the executive officers and approved in advance by a 2/3 vote of the Regents of the University of Michigan.

Background:

The Company is a for-profit entity, which develops for commercialization therapeutic small molecule inhibitors as anti-cancer agents. The Agreement is for participation by Dr. Wang in the experimental design and managing of the research activities. Dr. Wang will not conduct any specific experiments and will not generate any data or results. Dr. Liu Liu, is a Research Investigator in the Department of Internal Medicine, Division of Hematology/Oncology, and has no affiliation with the Company. Dr. Liu will design and perform certain biochemical studies for the designed compounds.

Nature of the Agreement:

Five new technologies, (OTT Files 4139, 4241, 4676, 4790 and 4791) will be used in this project. The Company has its own internal research efforts, distinct from what they are sponsoring in Dr. Wang's laboratory at the University. While Dr. Wang's lab will conduct the discovery research under the project, the Company will provide all pre-clinical development and clinical trials with the licensed technologies from the University.